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Recent studies in our laboratory have shown that PCP (phencyclidine) and D-amphetamine induce 
a cognitive deﬁ  cit in rats, in a paradigm of potential relevance for the pathology of schizophrenia. 
Atypical, but not classical antipsychotics and the anticonvulsant, lamotrigine have been shown 
to prevent a selective reversal learning deﬁ  cit induced by PCP . In contrast, only haloperidol 
reversed the D-amphetamine-induced deﬁ  cit. The present study aimed to explore the ability of 
two anticonvulsants with differing mechanism of action, valproate and phenytoin to attenuate 
the cognitive deﬁ  cits induced by PCP and D-amphetamine in the reversal learning paradigm. 
PCP at 1.5 mg/kg and D-amphetamine at 0.5 mg/kg both produced a selective and signiﬁ  cant 
reduction in performance of the reversal phase with no effect on the initial phase of the task 
in female-hooded Lister rats. Valproate (25–200 mg/kg) and phenytoin (25–50 mg/kg) had no 
effect on performance when administered alone. Valproate (100–200 mg/kg), whose principle 
action is thought to be the enhancement of GABA transmission, was unable to prevent the 
cognitive deﬁ  cit induced by either PCP or D-amphetamine. Conversely, phenytoin (50 mg/kg), 
a use-dependent sodium channel inhibitor, signiﬁ  cantly prevented the deﬁ  cit induced by PCP , 
but not D-amphetamine. These results add to our earlier work with lamotrigine, and suggest 
that sodium channel blockade may be a mechanism by which some anticonvulsant drugs can 
prevent the PCP-induced deﬁ  cit. These data have implications for the use of anticonvulsant 
drugs in the treatment of cognitive or psychotic disorders.
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afﬁ  nity for the 5-HT2A receptor and low afﬁ  nity for the dopamine 
D2 receptor prevented the disruption of reversal learning induced by 
PCP, and the anticonvulsant, lamotrigine, a use-dependent sodium 
channel blocker (Xie et al., 1995) that may act in part by inhibit-
ing glutamate release (Cunningham and Jones, 2000; Lingamaneni 
and Hemmings, 1999; Waldmeier et al., 1996), was also shown to 
be effective. Both compounds failed to prevent a d-amphetamine 
induced cognitive deﬁ  cit, which was attenuated by haloperidol 
(Idris et al., 2005).
These ﬁ   ndings suggest that different mechanisms underlie 
the cognitive impairment induced by PCP and d-amphetamine. 
We hypothesise that PCP induces a deﬁ  cit in the reversal learn-
ing task as a consequence of increased glutamate transmission 
arising downstream of NMDA receptor inhibition (Adams and 
Moghaddam, 1998; Moghaddam et al., 1997; Olney and Farber, 
1995). Currently used antipsychotic therapies do not target directly 
glutamate transmission, thus the validity of this hypothesis remains 
untested. However, several lines of evidence suggest that glutamate 
is involved in the pathophysiology of schizophrenia (Carlsson et al., 
1999; Deakin et al., 1989; Dursun et al., 1999; Hirsch et al., 1997; 
Tamminga, 1998, 1999), and a hyperglutamate hypothesis was ﬁ  rst 
proposed by Deakin et al. (1989) on the basis of neurochemical 
evidence of an excess of glutamatergic synapses in the frontal cortex 
of schizophrenic patients (Deakin and Simpson, 1997; Deakin et al., 
INTRODUCTION
The psychotomimetic noncompetitive N-methyl-d-aspartate 
receptor antagonist phencyclidine (PCP) can mimic many of the 
positive, negative and cognitive symptoms of schizophrenia in nor-
mal humans and precipitate a psychotic episode in schizophrenia 
patients in remission (Aniline and Pitts, 1982; Javitt, 1987; Jentsch 
and Roth, 1999; Steinpreis, 1996). NMDA receptor antagonists also 
disrupt the behaviour of animals, providing a model to investigate 
the mechanism by which these agents induce psychotic symptoms 
and perhaps some insight into the pathophysiology underlying 
schizophrenia (reviewed recently by Large, 2007) The study of these 
models led to the NMDA receptor hypofunction hypothesis of the 
pathophysiology of schizophrenia, which has stimulated interest in 
developing new medication strategies. These experimental strate-
gies include potentiation of NMDA receptor-mediated neurotrans-
mission, facilitation of GABAergic neurotransmission, and direct 
or indirect blockade of excessive release of glutamate. Increasing 
evidence suggests that agents that inhibit glutamate release may 
have some application in the treatment of cognitive dysfunction 
associated with schizophrenia (Muzina et al., 2002). Previously, we 
have shown that PCP induces a cognitive deﬁ  cit in rats in a reversal 
learning paradigm, which is believed to model aspects of cognitive 
impairments in schizophrenia (Abdul-Monim et al., 2003; Idris 
et al., 2005). The atypical antipsychotic, clozapine with its high 
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1997; Reynolds et al., 2001; Simpson et al., 1998). Importantly, PCP 
and ketamine have been shown to increase glutamate levels in the 
prefrontal cortex (López-Gil et al., 2006; Moghaddam et al., 1997). 
Furthermore, sub-chronic PCP treatment produces a signiﬁ  cant 
reduction in parvalbumin containing GABAergic interneurones 
in the frontal cortex (Abdul-Monim et al., 2003; Cochran et al., 
2002, 2003). This is consistent with human postmortem studies that 
indicate a deﬁ  cit in GABAergic neurons in the prefrontal cortex of 
schizophrenia patients (Beasley and Reynolds, 1997).
Anticonvulsant drugs are a group of compounds that suppress 
neuronal ﬁ  ring through a broad array of mechanisms. Phenytoin, 
like lamotrigine, has been shown to inhibit voltage-gated sodium 
channels and may also inhibit glutamate release (Kwan and Brodie, 
2000; Macdonald and Greenﬁ  eld, 1997). Sodium valproate has been 
shown to inﬂ  uence levels of GABA (Baldino and Geller, 1981; 
Loscher, 1989), and is unlikely to inﬂ  uence sodium channels at 
therapeutic concentrations. The present study aimed to explore 
further the mechanism by which lamotrigine prevents the PCP-
induced disruption of reversal learning by examining the efﬁ  cacy 
of these additional anticonvulsants that have differing mechanisms 
of action. For comparison with our previous studies with clozapine, 
haloperidol, and lamotrigine (Idris et al., 2005), we also examine the 
ability of the two drugs to prevent a disruption of reversal learning 
produced by d-amphetamine.
MATERIALS AND METHODS
SUBJECTS AND HOUSING CONDITIONS
Subjects were 40 female-hooded Lister rats (Harlan, UK) obtained 
as adults and randomly housed in groups of four (cages measured 
38 cm × 59 cm × 24 cm). Animals were maintained under stand-
ard laboratory conditions at a temperature of 21°C (±2°C) and 
humidity of 40–50%. They were maintained on a 12-h light/dark 
cycle (lights on at 07:00 hours) and the experimental procedure was 
undertaken in the last part of the light phase. Rats were gradually 
food deprived to approximately 85% of their free-feeding body 
weight (225–250 g). The reduced body weight was maintained by 
restricting the amount of food given (Standard laboratory chow, 
Special Diet Services, Essex, UK) to each rat per day (12 g/day). 
The availability of water was not restricted.
Experiments were carried out in accordance with the Animals 
Scientiﬁ  c Procedures Act, 1986 and were approved by the University 
of Bradford ethical review process.
APPARATUS
All rats were tested in one of eight identical operant chambers 
(constructed in-house). Each chamber (29 cm × 30 cm × 30 cm) 
consisted of Plexiglas walls and ceiling and metal grid ﬂ  oor over 
sawdust. A hinged Plexiglas panel (6 cm × 6 cm) provided access 
to a food hopper containing food pellets (25 mg Noyes pellets, 
Sandown Scientiﬁ  c, UK). Two retractable levers (4 cm × 2 cm) were 
positioned either side of the food hopper. A light emitting diode 
(LED) was positioned centrally above each lever and a house-light 
was located in the ceiling of each chamber. The chambers were 
placed individually within ventilated sound-attenuating hardboard 
boxes (69 cm × 38 cm × 42 cm) containing a Perspex window to 
allow viewing. A small fan was built into each chamber to mask 
external noise. Each animal was tested in the same operant chamber 
throughout the study. All boxes were controlled by Med-PC soft-
ware (Version 2.0 for DOS, Med Associates Inc. Lafayette, Indiana). 
Programmes were written using Medstate notation.
OPERANT TRAINING SESSIONS
Following habituation to the operant chambers, rats were trained 
to respond for food on an FR1 (Fixed Ratio 1) schedule of rein-
forcement with both levers active, as previously described (Abdul-
Monim et al., 2003). When responding stabilised, rats were trained 
to press either the left or right lever for food delivery. Both levers 
were present, but only one lever was active. The active lever was 
varied from day to day using a pseudorandom Gellerman schedule, 
which randomly assigns either the left or right lever as active, thus 
avoiding generation of a lever bias. Each session lasted 20 min and 
counts were recorded on each lever. This ﬁ  rst phase of training was 
complete in approximately 2 weeks.
As described previously (Abdul-Monim et al., 2003), the rats 
were then trained to respond for food according to the position of 
a visual cue (a lit LED). Half were trained to press the lever under 
the lit LED in order to receive a food reward, the other half were 
trained on the opposite contingency, in other words, to press the 
lever under the non-lit LED.
Each training session began with illumination of the house-light. 
After 3 s both levers, together with the visual cue, were presented. 
The cue was presented for 1 s. Following a lever press, a correct 
response resulted in delivery of a food pellet. The levers were then 
retracted and the house light was extinguished for a 3-s time-out 
period, during which the pellet was consumed (if a correct response 
had been made). The house-light was then turned on again and the 
cycle repeated. The experimental session was terminated following 
a total of 128 lever presses, which took approximately 30 min. Each 
rat had one training session per day. Rats were required to make at 
least 115 responses on the correct lever (90% correct responding) 
on at least three consecutive days, which they generally achieved 
within 2 weeks. The contingency (visual cue, i.e. LED on or off, rela-
tive to active lever) remained constant during this period, though 
the position of the active lever varied from day to day according to 
a pseudo-random Gellerman schedule. Subsequently, rats were 
trained until they again reached criterion on the opposite contin-
gency (again this generally took 2 weeks). Rats achieved criterion at 
the same rate irrespective of whether they responded to one rule or 
the other. Following a total of approximately 6 weeks of habituation 
and training, the reversal learning task was introduced.
REVERSAL LEARNING TASK
The day before each reversal task session, a full 30-min operant train-
ing session (as described above) was conducted in order to ensure 
stable responding. The reversal task session then took place as fol-
lows. Animals were ﬁ  rst exposed to a 5-min period during which the 
contingency (cue position relative to active lever) was the same as for 
the operant training session. During this period, responses on both 
correct and incorrect levers were recorded. This part of the session 
is termed the initial phase. This was followed by a 2-min time-out 
period, which was signalled by the house-light being turned off. In the 
subsequent 5-min period, the contingency was reversed. Responses 
made on the correct and incorrect levers were again recorded. This 
second period is termed the reversal phase. Animals undertook Idris et al.  Phenytoin and valproate
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June  2009 | Volume  3 | Article  8 | 3
  several of these reversal learning task sessions before the beginning 
of the drug studies in order to ensure that they attained stable level 
of performance in both phases of the task. In general, four to six 
sessions were required before this was achieved. In total, animals 
required about 6 weeks of training to reach this point.
EXPERIMENTAL DESIGN-DRUG STUDIES
An independent design was used in the present study and drug 
treated groups were compared with their appropriate controls. The 
experimental design typically consisted of a training day (day 1), 
followed by a drug test day for which the data are shown (day 2). 
On a drug test day, 40 animals were used in a complete drug study, 
e.g. to test effects of phenytoin versus PCP or d-amphetamine. 
On the following day, animals were trained on the same reversal 
task reward contingency used on the previous day (day 3) and 
on the next day, a drug free reversal test was performed to ensure 
that animals’ performance had returned to baseline levels (day 4). 
If baseline responding had been restored, this sequence of events 
would be repeated for the next drug study.
In this way, drug treatments were separated by at least 4 days and 
a drug-free reversal test was conducted before the next drug study 
began. The drug treatment given to each rat (and within each home-
cage) over the course of these six experiments was randomised. 
Every effort was made to keep the number of drug and vehicle 
treatments equivalent between animals and to randomise the order 
of treatments (treatments for an example animal are shown in the 
ﬁ  nal column of Table 1). Thus if an animal received vehicle in 
experiment 1, it received a drug combination in experiment 2 and 
so on. As all drugs were given acutely, baseline performance was 
restored following the drug-free training session.
Results are only shown for day 2, i.e. the drug test day. The 
general design for testing and training is shown below:
Day 1 –  training, approximately 30 min.
Day 2 –   test day for drug study 1, two 5 min tests (initial and reversal 
phases). 40 animals tested in a complete drug study.
Day 3 –   re-training on the same reward contingency used in the 
reversal task of the drug test day (day 2), approximately 
30 min.
Day 4 –   drug free reversal test, two 5 min tests (initial and reversal 
phases).
Day 5 –   re-training on the same reward contingency used in the 
reversal task of the previous day, approximately 30 min.
Day 6 –  re-training, approximately 30 min.
Day 7 –   test day for drug study 2, two 5 min tests (initial and 
reversal phases) and so on….
This regimen was repeated for each drug study carried out, with 
40 rats used to test the effects of each drug combination (n = 8–10 
rats per group). Forty rats were used for all these drug studies. 
Baseline performances were restored before the next drug study 
was conducted, as shown above and control levels of perform-
ance in this task had not changed signiﬁ  cantly by the end of these 
experiments (see Results).
DRUGS
All drugs were administered in a volume of 1 ml/kg via the intra-
peritoneal route (i.p.). Drug doses were calculated as the base equiv-
alent weight. PCP and d-amphetamine were administered 30 min 
prior to testing. In the event of co-administration, sodium valproate 
or phenytoin was given 30 min prior to administration of PCP or 
d-amphetamine. Phenytoin (Sigma, Germany), sodium valproate 
(Sigma, Germany) d-amphetamine (Sigma, UK) and PCP HCl 
(Sigma, UK) were dissolved in distilled water. The doses for PCP 
and d-amphetamine were selected on the basis of our previous dose 
response studies in the reversal learning paradigm, as described 
in Idris et al., (2005). The doses of anticonvulsants, valproate and 
phenytoin were based on previous studies (Farber et al., 2002a) 
and from personal communications (C. Large, GSK).
STATISTICAL ANALYSIS
Data from this study are presented in two ways: mean total number 
of lever presses (±S.E.M.) and percent correct responses (±S.E.M.); 
in each case values for the initial and reversal phase are presented for 
the different drug treatment groups. The raw lever press data were 
used to determine whether there were signiﬁ  cant effects of phase 
of task or drug(s) on overall responding (e.g. that might reﬂ  ect 
changes in motor co-ordination or motivation). The percentage 
correct response data were used to determine whether there was 
a signiﬁ  cant effect of phase of task or drug(s) on response accu-
racy (e.g. that might reﬂ  ect cognitive dysfunction); these data were 
Arc-Sin transformed prior to analysis. Statistical signiﬁ  cance was 
assumed when P < 0.05 and was determined as follows:
Analysis of Variance for repeated measures was performed in 
order to detect main effect of drug(s) treatment. Where a signiﬁ  cant 
effect was detected, a post hoc Dunnett’s test was performed in order 
to compare treatment groups versus the appropriate control.
RESULTS
BASELINE LEVELS OF PERFORMANCE
Rats were regularly tested to determine whether baseline per-
formance was disrupted over the course of the study (approxi-
mately 8 weeks). At the beginning of the study the mean ± S.E.M. 
Table 1 | The order of drug experiments and an example of the drug treatments for one rat.
Experiment  Test drug  Challenge drug  An example animal
1  Sodium valproate 100–200 mg/kg  None  Sodium valproate 200 mg/kg + vehicle
2  Sodium valproate 100–200 mg/kg  PCP 1.5 mg/kg  Vehicle + PCP 1.5 mg/kg
3  Sodium valproate 100–200 mg/kg  Amphetamine 0.5 mg/kg  Sodium valproate 200 mg/kg + amphetamine 0.5 mg/kg
4 Phenytoin  25–100  mg/kg  None  Vehicle  + vehicle
5  Phenytoin 25–100 mg/kg  PCP 1.5 mg/kg  Phenytoin 100 mg/kg + PCP 1.5 mg/kg
6  Phenytoin 25–100 mg/kg  Amphetamine 0.5 mg/kg  Vehicle + amphetamine 0.5 mg/kgIdris et al.  Phenytoin and valproate
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  percentage correct responding in the initial phase was 82.9 ± 3.52 
and 79.6 ± 1.84 for the reversal phase. The average values were 
89.5 ± 3.22 (initial phase) and 80.38 ± 3.56 (reversal phase) at the 
end of the drug studies.
EXPERIMENT 1: PHENYTOIN DOSE-RESPONSE EVALUATION
The vehicle treated group made 22.7 ± 1.8 (mean ± S.E.M., n = 10) 
correct responses out of a total of 27.3 ± 1 lever presses in the ini-
tial phase and 22.4 ± 1.2 out of 28.2 ± 0.9 in the reversal phase of 
the task (Figure 1A). Phenytoin (25 and 50 mg/kg) had no effect 
on the accuracy of responding in the initial or reversal phases of the 
task, but did cause a signiﬁ  cant reduction in the total number of 
lever presses in the reversal phase alone at 25 mg/kg (P < 0.01) and 
in both phases at 50 mg/kg (P < 0.001; Figure 1A). At 100 mg/kg, 
phenytoin signiﬁ  cantly reduced correct responding in both the 
initial and reversal phases of the task (P < 0.05; Figure 1B). This 
impairment was accompanied by a highly signiﬁ  cant reduction 
in the total number of lever presses in both the initial and the 
reversal phases of the task (P < 0.001; Figure 1A). Overall analysis 
of the experiment suggests that there was no signiﬁ  cant effect of 
  phenytoin on correct responding in the reversal phase when com-
pared with the initial phase [F (3, 36) = 0.5, NS; Figure 1B].
EXPERIMENT 2: EFFECT OF PHENYTOIN ON PCP-INDUCED IMPAIRMENT
The vehicle treated group made 24.8 ± 0.6 (mean ± S.E.M., n = 8) 
correct responses out of a total of 27.5 ± 0.4 in the initial phase 
and 24.1 ± 0.7 out of 27.6 ± 0.7 in the reversal phase of the task 
(Figure 2A). Overall analysis showed that there was a signiﬁ  cant 
effect of phase of task on correct responding [F (1, 35) = 6.9, 
P < 0.05] and a signiﬁ  cant effect of drug treatment on correct 
responding [F (4, 35) = 3.4, P < 0.05] such that animals made 
fewer correct responses in the reversal phase compared to the ini-
tial phase of the task (Figure 2B). Post hoc analysis showed that 
PCP (1.5 mg/kg) signiﬁ  cantly reduced correct responding in the 
reversal, but not initial phase of the task (P < 0.01). This reduction 
was dose-dependently and signiﬁ  cantly attenuated by phenytoin 
(25–50 mg/kg, P < 0.05; Figure 2B). However, the highest dose of 
phenytoin (100 mg/kg) signiﬁ  cantly reduced correct responding 
in both the initial and reversal phases of the task (P < 0.01), as 
observed in the ﬁ  rst experiment. Phenytoin signiﬁ  cantly reduced 
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FIGURE 1 | (A) The inﬂ  uence of phenytoin (25–100 mg/kg, i.p.) on 
performance of the initial and reversal phase of the reversal learning task. Data 
are shown as the mean total number of lever presses, correct responses are 
shown as clear bars and incorrect responses are shown as shaded bars 
(n = 10 per group). (B) The inﬂ  uence of phenytoin (25–100 mg/kg, i.p.) on 
performance of the initial and reversal phase of the reversal learning task. Data 
are shown as mean ± S.E.M. percentage correct responding (n = 10 per 
group). Signiﬁ  cant reduction in performance of the initial and reversal phase 
compared with the respective vehicle group; †P < 0.05, ††P < 0.01; ANOVA 
followed by Dunnett’s t-test.Idris et al.  Phenytoin and valproate
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total lever pressing in both phases of the task at 50 mg/kg (P < 0.01) 
and 100 mg/kg (P < 0.001; Figure 2A).
EXPERIMENT 3: EFFECT OF PHENYTOIN ON AMPHETAMINE-INDUCED 
IMPAIRMENT
The vehicle treated group in this experiment made 24.5 ± 1.3 
(mean ± S.E.M.,  n  =  10) correct responses out of a total of 
28 ± 0.9 in the initial phase, and 22.6 ± 0.9 out of 26.5 ± 0.7 in 
the reversal phase (Figure 3A). Overall analysis of the experi-
ment suggests that there was a signiﬁ  cant effect of phase of the 
task on correct responding [F (1, 35) = 5.0, P < 0.01] and also 
a signiﬁ  cant effect of drug treatment on correct responding [F 
(4, 35) = 4.5, P < 0.01] such that animals made fewer correct 
responses   during the reversal phase than the initial phase of the 
task. Post hoc analysis showed that d-amphetamine (0.5 mg/kg) 
signiﬁ  cantly reduced correct responding in the reversal phase 
(P <  0.001), with no effect on the initial phase of the task. 
Phenytoin (25–100 mg/kg) did not prevent the reduction in 
correct responding induced by d- amphetamine.  Furthermore, 
correct responding was signiﬁ  cantly reduced by phenytoin at 
100 mg/kg in the presence of d-amphetamine in both initial and 
reversal phases of the task when compared with the respective 
vehicle groups (P < 0.01; Figure 3B). d-amphetamine alone pro-
duced a small, but signiﬁ  cant reduction in total lever pressing in 
the reversal phase when compared with the appropriate vehicle 
group. In the presence of d-amphetamine, phenytoin (25 mg/kg) 
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FIGURE 2 | (A) The inﬂ  unce of phenytoin pretreatment (25–100 mg/kg, i.p.) 
on the effect of PCP (1.5 mg/kg, i.p.) on performance of the initial and reversal 
phase of the reversal learning task. Data are shown as the mean total number 
of lever presses, correct responses are shown as clear bars and incorrect 
responses are shown as shaded bars (n = 8 per group). (B) The effect of 
phenytoin pretreatment (25–100 mg/kg, i.p.) on the deﬁ  cit produced by PCP 
(1.5 mg/kg, i.p.) on performance of the reversal phase in a reversal learning 
task. Data are shown mean ± S.E.M. percentage correct responding 
(n = 8 per group). Signiﬁ  cant reduction in performance of the reversal phase 
compared with the initial phase; *P < 0.05, **P < 0.01. Signiﬁ  cant reduction in 
performance of the reversal phase compared with the vehicle, vehicle 
controls; ††P < 0.01. Signiﬁ  cant improvement in responding compared to PCP 
alone in the reversal phase; #P < 0.05, ANOVA followed by Dunnett’s 
t-test.Idris et al.  Phenytoin and valproate
Frontiers in Behavioral Neuroscience  www.frontiersin.org  June  2009 | Volume  3 | Article  8 | 6
signiﬁ  cantly reduced lever pressing in the initial phase alone 
(P < 0.05), whereas at 50 and 100 mg/kg phenytoin signiﬁ  cantly 
reduced total lever pressing in both the initial and reversal phases 
(P < 0.05, P < 0.01, respectively, Figure 3A).
EXPERIMENT 4: VALPROATE DOSE-RESPONSE EVALUATION
The vehicle treated group made 24.3 ± 1.4 (mean ± S.E.M., n = 10) 
correct responses out of a total of 27.8 ± 0.3 lever presses in the 
initial phase and 20.9 ± 1.8 out of 28.3 ± 0.3 in the reversal phase 
(Figure 4A). Overall analysis suggests that there was no signiﬁ  cant 
effect of phase of the task on correct responding [F (1, 36) = 0.58, 
NS]. There was no signiﬁ  cant effect of valproate (100–200 mg/kg 
i.p.) on correct responding [F (3, 36) = 0.92, NS] or on the total 
number of lever presses [F (3, 36) = 1.9, NS; Figures 4A,B].
EXPERIMENT 5: EFFECT OF VALPROATE ON PCP-INDUCED IMPAIRMENT
The vehicle treated group in this experiment made 24.3  ± 1.4 
(mean ± S.E.M., n = 8) correct responses out of a total of 27.8 ± 0.3 
in the initial phase and 20.9 ± 1.9 out of 28.3 ± 0.3 in the reversal 
phase of the task (Figure 5A). Overall analysis showed that there 
was a signiﬁ  cant effect of phase of task on correct respond-
ing [F (1, 35) = 33.4, P < 0.001] and a signiﬁ  cant effect of drug 
treatment on correct response [F (4, 35) = 15.4, P < 0.01] such 
that   animals made fewer correct responses in the reversal phase 
  compared to the initial phase of the task (Figure 5B). Post hoc 
analysis showed that PCP (1.5 mg/kg) signiﬁ  cantly reduced cor-
rect responding in the reversal, but not in the initial phase of the 
task (P < 0.01; Figure 5B). Valproate (100–200 mg/kg) did not pre-
vent the reduction in correct responding induced by PCP, since 
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FIGURE 3 | (A) The effect of phenytoin pretreatment (25–100 mg/kg, i.p.) on the 
deﬁ  cit produced by D-amphetamine (0.5 mg/kg, i.p.) on performance of the initial 
and reversal phase of the reversal learning task. Data are shown as the mean 
total number of lever presses, correct responses are shown as clear bars and 
incorrect responses are shown as shaded bars (n = 8 per group). (B) The effect of 
phenytoin pretreatment (25–100 mg/kg, i.p.) on the deﬁ  cit produced by 
D-amphetamine (0.5 mg/kg, i.p.) on performance of the reversal phase in a 
reversal learning task. Data are shown as mean ± S.E.M. percentage correct 
responding (n = 8 per group). Signiﬁ  cant reduction in performance of the reversal 
phase compared with the initial phase; *P < 0.05, **P < 0.01, ***P < 0.001. 
Signiﬁ  cant reduction in performance of the initial and reversal phase compared 
with the respective vehicle group; ††P < 0.01, ANOVA followed by Dunnett’s t-test.Idris et al.  Phenytoin and valproate
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in the presence of valproate there was still a signiﬁ  cant reduction 
in correct responding in the reversal phase when compared with 
the initial phase (P < 0.001, P < 0.01 respectively; Figure 5B). PCP 
alone had no signiﬁ  cant effect in the total number of lever presses, 
but valproate at 150–200 mg/kg plus PCP produced a small, but 
signiﬁ  cant reduction in the total number of lever presses in both 
the initial and the reversal phases of the task when compared with 
the vehicle group (P < 0.05; Figure 5A).
EXPERIMENT 6: EFFECT OF VALPROATE ON AMPHETAMINE-INDUCED 
IMPAIRMENT
The vehicle treated group in this experiment made 24.9 ± 0.9 
(mean ± S.E.M., n = 8) correct responses out of a total of 27.8 ± 0.3 
in the initial phase and 22.5 ± 1.2 out of 28.1 ± 0.5 in the reversal 
phase (Figure 6A). Overall analysis suggests that there was a 
signiﬁ  cant effect of phase of the task on correct responding 
[F (1, 35) = 41.6, P < 0.001] and also a signiﬁ  cant effect of drug 
treatment on correct responding [F (4, 35) = 5.5, P < 0.001] such 
that animals made fewer correct responses in the reversal phase 
compared to the initial phase of the task (Figure 6B). Post hoc 
analysis showed that d-amphetamine (0.5 mg/kg) signiﬁ  cantly 
reduced correct responding in the reversal phase [F (1, 35) = 10.5, 
P <  0.001], with no effect on  the initial phase of the task 
(Figure 6B). Valproate 100–200 mg/kg) did not prevent the reduc-
tion in   correct responding induced by d-amphetamine, since a 
signiﬁ  cant reduction in correct responding in the reversal phase 
was still observed with the addition of valproate (100–200 mg/
kg) in the presence of d-amphetamine when compared with ini-
tial phase (P < 0.05 to P < 0.001, n = 8 per group; Figures 6A,B). 
Neither d-  amphetamine alone nor   valproate at 100–200 mg/kg 
plus 0.5 mg/kg d- amphetamine had a signiﬁ  cant effect in the total 
number of lever presses (Figure 6A).
DISCUSSION
THE REVERSAL LEARNING TASK
The current study conﬁ  rms previous work showing that doses 
of 1.5 mg/kg of PCP and 0.5 mg/kg of amphetamine produce a 
selective deﬁ  cit in the reversal phase of the reversal leaning task. 
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In the presence of the two psychotomimetic drugs, animals were 
able to maintain performance of the initial task requiring memory 
for the learned rule. However, in the reversal phase, where animals 
are required to stop responding according to the original rule, 
and respond in the opposite manner, both drugs signiﬁ  cantly 
affected performance.. Thus, PCP and d-amphetamine signiﬁ  -
cantly impaired performance of a complex cognitive task with-
out disrupting simple rule directed responding. Such patterns of 
cognitive deﬁ  cit have been clearly demonstrated in schizophrenia, 
for example the inability of patients to perform the Wisconsin 
card-sorting test (Lidde, 2000). PCP or d-amphetamine alone 
did not affect the total number of lever presses, irrespective of 
the phase of the task, which would suggest no sedation, behav-
ioural or motivational impairment induced by these compounds 
at the doses used here. Thus, the deﬁ  cits observed were due to 
incorrect responding rather than a loss in ability or motivation 
to lever press.
PHENYTOIN
Phenytoin signiﬁ  cantly impaired responding in the reversal learn-
ing paradigm in a manner that was not related to the phase of the 
task; however, despite this, the drug did appear to preserve the 
accuracy of responses (% correct responding), and also signiﬁ  -
cantly prevented the reduction in response accuracy induced by 
PCP in the reversal phase of the task. Previously, we have shown 
that lamotrigine could also reduce the effect of PCP on response 
accuracy in the reversal phase, but lamotrigine had the advan-
tage that it did not affect the number of lever presses (Idris et al., 
2005). Furthermore, both lamotrigine and phenytoin can pre-
vent the neurotoxic effects of the potent non-competitive NMDA 
antagonist MK-801 (Farber et al., 2002b). These data suggest that 
the mechanism of action of these agents to improve the reversal 
learning deﬁ  cit induced by PCP (i.e. an inhibition of voltage-gated 
sodium channels inducing decreased release of glutamate) prob-
ably underlies their ability to prevent the PCP induced   disruptive 
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effect including NRHypo neurotoxicity (Farber, 2003; Farber 
et al., 2002b). To begin to understand the mechanism(s) under-
lying the consequence of the NRHypo state in humans, several 
research groups have begun examining the consequence of PCP 
a non-competitive NMDA receptor antagonist induced NRHypo 
in adult rodents. One typical consequence is excessive release of 
glutamate (Moghaddam et al., 1997; Noguchi et al., 1998) in the 
prefrontal cortex. It has been proposed that this excessive release 
of excitatory neurotransmitters and consequent overstimulation of 
postsynaptic neurons might explain the cognitive deﬁ  cits associated 
with NMDA receptor antagonism (Moghaddam et al., 1997; Olney 
et al., 1989). These data indicate that inhibition of voltage-gated 
sodium channels is a likely mechanism through which these agents 
prevent the cognitive deﬁ  cit induced by PCP.
In the case of phenytoin, the strong effect of the drug to reduce 
lever pressing makes it difﬁ  cult to draw the same conclusion, 
despite the positive statistical analysis. However, consistent with 
previous results with lamotrigine (Idris et al., 2005), phenytoin 
was unable to prevent the disruption of reversal phase performance 
by d- amphetamine  despite  signiﬁ  cantly reducing lever pressing. 
A comparison between the PCP and d-amphetamine experiments 
thus provides conﬁ  dence that the prevention by phenytoin of the 
reduction in correct responding by PCP was not a statistical arti-
fact. In conclusion, we suggest that the results with phenytoin add 
support to the hypothesis that sodium channel blockers have a ben-
eﬁ  cial effect on the disruption by PCP of a cognitive task; however, 
overall responding was signiﬁ  cantly impaired by phenytoin, and 
this might preclude the use of this drug in a therapeutic setting.
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i.p.) on the effect of D-amphetamine (0.5 mg/kg, i.p.) on performance of the 
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SODIUM VALPROATE
Sodium valproate had little or no effect on performance of either 
phase of the reversal learning task. A minor reduction in lever press-
ing was observed only at the highest dose tested during the reversal 
phase of the task. However, valproate failed to reduce the disruption 
by PCP or d-amphetamine of correct responding in the reversal 
phase of the reversal learning task. This result is consistent with 
previous studies that found that valproate was unable to prevent 
ketamine- or d-amphetamine-induced disruption of prepulse 
inhibition in mice (Ong et  al., 2005). Furthermore, valproate 
was unable to prevent an increase in locomotor activity induced 
by d- amphetamine  (Arban et al., 2005). The doses of valproate 
used in the present study were considered sufﬁ  cient, since doses 
of 75 and 150 mg/kg, given orally, were found to be effective at 
preventing increases in locomotor activity induced by a mixture 
of d-amphetamine and chlordiazepoxide (Arban et al., 2005), and 
doses in the range of 50–200 mg/kg, given by the intraperitoneal 
route are anticonvulsant in rodent models of seizure (C. Large, 
unpublished observations). Furthermore, in the present study, val-
proate at all doses did produce a reduction in lever pressing when 
in combination with PCP. These data indicate a pharmacodynamic 
interaction between valproate and PCP. A similar interaction was 
observed in the study by Arban et al. (2005), which found that val-
proate enhanced the sedating effects of chlordiazepoxide, consistent 
with the ability of valproate to enhance GABAergic transmission 
(Baldino and Geller, 1981; Loscher, 1989). In contrast, no reduction 
in lever pressing was observed in the present study with the com-
bination of valproate and d-amphetamine, suggesting that there 
was no pharmacodynamic interaction in this case.
CONCLUSIONS
The present study adds to previous results with the reversal learn-
ing paradigm and supports the efﬁ  cacy of sodium channel block-
ing drugs to prevent disruption of the reversal phase of the task by 
NMDA receptor antagonists. These results are also consistent with 
the hypothesis that the behavioural disruption induced by PCP is 
linked to an increase in glutamate transmission, since phenytoin, like 
lamotrigine, has been shown to reduce glutamate release under some 
circumstances (Cunningham and Jones, 2000). In addition, this study 
adds to data from other models suggesting that enhancing GABAergic 
transmission does not reduce the effects of PCP, but instead can 
exacerbate effects. This ﬁ  nding apparently contradicts the proposed 
mechanism by which low doses of NMDA receptor antagonists cause 
a reduction in GABAergic feedback, which then leads to a disinhibi-
tion of principal neurons in cortex and hippocampus (Olney and 
Farber, 1995). However, the majority of the data linking valproate to 
increased GABA transmission is derived from chronic dosing studies 
(see also Schechter et al., 1978), so it remains to be demonstrated that 
the drug does increase GABA in an acute setting.
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